Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Petru, E; Schwarz, S; Benedicic, C; Reuss, J; Haas, J; Winter, R.
Goserelin as palliative treatment in ovarian and endometrial carcinoma
GEBURTSH FRAUENHEILK. 2004; 64: 831-834. Doi: 10.1055/s-2004-821148
Web of Science FullText FullText_MUG

Leading authors Med Uni Graz: Petru Edgar
Co-authors Med Uni Graz: Haas Josef; Winter Raimund
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Purpose: Third or fourth line palliative chemotherapy in ovarian or endometrial cancer usually leads to remission rates of less than 20%. However, it is often associated with significant toxicity and high treatment costs. Alternatives are needed. The aim of this study was to retrospectively analyze the therapeutic results of the gonadotrophin-releasing hormone analogue goserelin in the treatment of advanced ovarian and endometrial cancer at our institution. Predictive factors for a clinical benefit (= stabilization for greater than or equal to 6 months) were supposed to be identified. Material and Methods: Between 2000 and 2003, a total of 51 consecutive patients with advanced ovarian or endometrial cancer were treated with monthly cycles of goserelin (3.6 mg s.c.). Patients were clinically evaluated on a monthly basis regarding their tumor-related symptoms. Patients underwent a gynecologic exam, abdominal and/or vaginal sonography at 3-month intervals or if signs of clinical progression were present; CA-125 levels were also evaluated monthly. On the basis of these findings, the clinical benefit was stated. Results: Overall, the rate of clinical benefit was 24% (12 out of 51 patients). With regard to potential predictive factors, neither tumor entity nor age and the other factors analyzed were predictive of a "response". Conclusion: The antihormonal therapy with monthly goserelin represents a minimally toxic form of palliative therapy. Goserelin leads to clinical benefit in 20 to 25% of patients. Thus, goserelin fulfils the patients' preference for continuation of systemic therapy without significantly compromising their quality of life during their last months of life.
Find related publications in this database (Keywords): GnRH analogues; goserelin; ovarian cancer; endometrial cancer; palliative therapy